Pharmafile Logo
Pharmafocus logo
Advanced Search

denosumab

Showing 7 posts of 7 posts found.

FDA approves Sandoz’s denosumab biosimilars

March 6, 2024
Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab

Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …

News

Boan Biotech completes enrolment for phase 3 study of Denosumab

January 15, 2024
Research and Development Boan Biotech, Pharmacy, biosimilar, clinical trial, denosumab

Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of …

News
amgen_hq

Amgen’s Prolia achieves positive top-line Phase III results after 12 months

August 30, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III

Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …

News
NICE image

NICE recommends Xgeva for bone metastasis

March 29, 2012
Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer

NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …

News

Amgen bone cancer drug Xgeva approved in Europe

July 18, 2011
Sales and Marketing Amgen, Prolia, Xgeva, denosumab

Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …

News
Amgen HQ

Amgen aims for oncology expansion and a wider denosumab license

January 12, 2011
Research and Development AMG- 479, AMG-386, Amgen, Cancer, Pancreatic cancer, denosumab, motasenib

Amgen is seeking to increase the use of its bone drug denosumab and further its reach into the oncology market, …

News

Denosumab approved for bone cancer use

November 19, 2010
Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab

Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026